Literature DB >> 6507482

Prenatal diagnosis and fetal pathology of aspartylglucosaminuria.

P Aula, J Rapola, H von Koskull, P Ammälä.   

Abstract

The prenatal diagnosis of aspartylglucosaminuria (AGU), a lysosomal storage disorder of glycoprotein degradation, was made by demonstrating the deficiency of N-aspartylglucosaminidase on cultured cells from a midterm amniotic fluid sample. Four other amniotic fluid studies from at-risk pregnancies gave a normal or a heterozygote level of enzyme activity. These pregnancies have gone to term and the delivery of healthy babies. The pregnancy with the affected fetus was terminated and the prenatal diagnosis was verified by enzyme assays on cord blood lymphocytes, cultured cells from skin biopsy, and from placental villi. Electron microscopic evidence of lysosomal storage was seen in several organs of the fetus with the notable exception of the central nervous system. The undifferentiated mesenchymal fibroblasts particularly were heavily loaded with cytoplasmic inclusions in skin, liver, kidney, and placenta.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6507482     DOI: 10.1002/ajmg.1320190218

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  4 in total

1.  Aspartylglycosaminuria presenting with hepatosplenomegaly in early infancy.

Authors:  J C Haworth; L E Seargeant; L A Dilling
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

2.  Amniotic fluid glycoasparagines in fetal aspartylglycosaminuria.

Authors:  I Mononen; V Kaartinen; T Mononen
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

3.  Applications of a new fluorimetric enzyme assay for the diagnosis of aspartylglucosaminuria.

Authors:  J L Keulemans; W J Kleijer; P Aula; G R Gray; O P van Diggelen
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

Review 4.  Aspartylglycosaminuria: a review.

Authors:  Maria Arvio; Ilkka Mononen
Journal:  Orphanet J Rare Dis       Date:  2016-12-01       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.